Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (R2-CHOP2)

This study has been completed.
Sponsor:
Collaborator:
Centre Henri Becquerel
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier:
NCT01393756
First received: July 4, 2011
Last updated: February 16, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2015
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)